ADMA Biologics (ADMA)
(Real Time Quote from BATS)
$19.39 USD
+0.10 (0.52%)
Updated Sep 25, 2024 03:00 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for ADMA Biologics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 51 | 87 | 51 | 56 | 27 |
Receivables | 27 | 16 | 29 | 13 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 173 | 163 | 125 | 82 | 53 |
Other Current Assets | 5 | 5 | 4 | 3 | 3 |
Total Current Assets | 257 | 270 | 209 | 154 | 86 |
Net Property & Equipment | 54 | 58 | 51 | 42 | 32 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 10 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 5 | 5 | 6 | 7 |
Deposits & Other Assets | 5 | 5 | 4 | 2 | 3 |
Total Assets | 329 | 348 | 276 | 208 | 127 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 16 | 13 | 12 | 11 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 0 | 0 |
Accrued Expenses | 33 | 25 | 17 | 8 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 50 | 39 | 30 | 20 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 2 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 131 | 143 | 95 | 93 | 83 |
Non-Current Capital Leases | 10 | 11 | 7 | 4 | 1 |
Other Non-Current Liabilities | 2 | 2 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 194 | 196 | 135 | 119 | 101 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 641 | 630 | 553 | 429 | 291 |
Retained Earnings | -506 | -478 | -412 | -340 | -265 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 135 | 152 | 141 | 88 | 26 |
Total Liabilities & Shareholder's Equity | 329 | 348 | 276 | 208 | 127 |
Total Common Equity | 135 | 152 | 141 | 88 | 26 |
Shares Outstanding | 226.00 | 221.80 | 195.80 | 104.90 | 59.30 |
Book Value Per Share | 0.60 | 0.69 | 0.72 | 0.84 | 0.44 |
Fiscal Year End for ADMA Biologics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 88 | 45 | 51 | 74 | 63 |
Receivables | 30 | 50 | 27 | 31 | 37 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 180 | 178 | 173 | 163 | 162 |
Other Current Assets | 6 | 4 | 5 | 5 | 5 |
Total Current Assets | 304 | 276 | 257 | 274 | 266 |
Net Property & Equipment | 54 | 55 | 54 | 55 | 56 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 10 | 0 | 0 |
Intangibles | 4 | 4 | 4 | 4 | 4 |
Deposits & Other Assets | 5 | 6 | 5 | 7 | 6 |
Total Assets | 376 | 351 | 329 | 349 | 343 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 17 | 16 | 11 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 28 | 34 | 33 | 30 | 29 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 44 | 53 | 50 | 42 | 42 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 2 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 131 | 131 | 131 | 142 | 140 |
Non-Current Capital Leases | 9 | 9 | 10 | 10 | 10 |
Other Non-Current Liabilities | 2 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 188 | 197 | 194 | 198 | 196 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 645 | 642 | 641 | 640 | 638 |
Retained Earnings | -456 | -488 | -506 | -489 | -491 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 188 | 154 | 135 | 151 | 147 |
Total Liabilities & Shareholder's Equity | 376 | 351 | 329 | 349 | 343 |
Total Common Equity | 188 | 154 | 135 | 151 | 147 |
Shares Outstanding | 233.00 | 231.70 | 226.00 | 225.90 | 224.50 |
Book Value Per Share | 0.81 | 0.66 | 0.60 | 0.67 | 0.65 |